CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1187953 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-50.0%
TTM net income YoY-25.4%
TTM EPS YoY29.9%
Revenue 3-yr CAGR-50.4%
Net income 3-yr CAGR—
Margins
Gross margin66.9%
Operating margin-256,435.0%
Net margin-249,160.1%
FCF margin—
EBITDA margin—
Returns
ROE-119.2%
ROA-113.8%
ROIC (approx.)-3,736.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.0%
Debt / equity0.00x
Current ratio23.66x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-16.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $6,000 | $11,000 | $9,000 | $88,600 | $87,754 |
| Cost of revenue | $2,194 | $4,400 | $3,600 | $28,491 | $47,949 |
| Gross profit | $3,806 | $6,600 | $5,400 | $60,109 | $39,805 |
| R&D expense | $2.26M | $2.40M | $1.97M | $6.27M | $109,180 |
| SG&A expense | $3.76M | $3.24M | $3.56M | $3.94M | $2.96M |
| Operating income | -$6.14M | -$5.74M | -$5.62M | -$10.24M | -$3.13M |
| Interest expense | — | — | — | $0 | $4.28M |
| Pretax income | -$6.00M | -$5.49M | -$5.29M | -$10.14M | $19.21M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$6.00M | -$5.49M | -$5.29M | -$10.14M | $19.21M |
| EBITDA | — | -$5.69M | -$5.56M | — | — |
| EPS (basic) | — | — | — | -0.93 | 7.37 |
| EPS (diluted) | -2.52 | -3.71 | -3.76 | -0.93 | 5.61 |
| Weighted avg. shares (diluted) | 2.38M | 1.48M | 1.41M | 10.93M | 3.25M |
| Balance sheet | |||||
| Cash & equivalents | $7.21M | $5.94M | $3.47M | $8.32M | $10.72M |
| Receivables | — | — | — | $0 | $2,485 |
| Inventory | $0 | $2,194 | $6,594 | $10,194 | $10,866 |
| Current assets | $7.40M | $6.14M | $10.27M | $18.75M | $10.74M |
| Intangibles | $407,230 | $530,559 | $441,011 | $435,595 | $527,679 |
| Total assets | $7.81M | $6.67M | $10.72M | $19.19M | $11.27M |
| Current liabilities | $284,880 | $327,644 | $371,394 | $3.32M | $1.05M |
| Total liabilities | $284,880 | $327,644 | $371,394 | $3.32M | $1.05M |
| Shareholders' equity | $7.51M | $6.34M | $10.34M | $15.86M | $10.22M |
| Shares outstanding | 3.70M | 1.75M | 1.37M | 1.41M | 6.34M |
| Cash flow statement | |||||
| Operating cash flow | -$5.86M | -$5.30M | -$8.03M | -$7.80M | -$2.22M |
| Investing cash flow | -$50,500 | $6.32M | $3.45M | -$10.08M | $0 |
| Financing cash flow | $7.17M | $1.45M | -$270,952 | $15.47M | $12.84M |
| Depreciation & amortization | — | $56,000 | $56,000 | — | — |
| Stock-based compensation | $3,485 | $36,648 | $36,648 | $68,746 | $595,380 |
| Share buybacks | $10,000 | $174,964 | $270,952 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.